• <table id="4yyaw"><kbd id="4yyaw"></kbd></table>
  • <td id="4yyaw"></td>
  • 發布時間:2019-08-03 22:21 原文鏈接: DownregulatedofMTA3inERnegativeBreastTumors

    Approximately 30% of breast carcinomas lack ER expression. Presumably, these breast cancers become estrogen independent through genetic alterations that bypass the requirement for ER-dependent stimulation of cell proliferation. As such estrogen receptor is a key regulator of proliferation and differentiation in mammary epithelia and represents a crucial prognostic indicator and therapeutic target in breast cancer. Mechanistically, estrogen receptor induces changes in gene expression through direct gene activation of a number of genes (cathepsin D, HSP27 (heat shock protein 27,000 kDa, aldolase A, dehydrogenase, alpha-tubulin, and glyceraldehyde-3-phosphat, Pdzk1, Greb ets) and also through the biological functions of target loci. The product of human MTA3 has been identified as an estrogen-dependent component of the Mi-2/NuRD transcriptional corepressor in breast epithelial cells and demonstrate that MTA3 constitutes a key component of an estrogen-dependent pathway regulating growth and differentiation. The absence of estrogen receptor or of MTA3 leads to aberrant expression of the transcriptional repressor Snail, a master regulator of epithelial to mesenchymal transitions. Aberrant Snail expression results in loss of expression of the cell adhesion molecule E-cadherin, an event associated with changes in epithelial architecture and invasive growth. MTA3 is the mechanistic link between estrogen receptor status and invasive growth of breast cancers.

    Contributor: Kosi Gramatikoff, PhD

    REFERENCES: Bieche I et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.Cancer Res. 2001 Feb 15;61(4):1652-8. PMID: 11245479 Fujita N et al. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.Cell. 2003 Apr 18;113(2):207-19. PMID: 12705869 Ghosh MG et al. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.Cancer Res. 2000 Nov 15;60(22):6367-75. PMID: 11103799 Kumar R. Another tie that binds the MTA family to breast cancer.Cell. 2003 Apr 18;113(2):142-3. Review. PMID: 12705862 Pethe V, Shekhar PV. Estrogen inducibility of c-Ha-ras transcription in breast cancer cells...J Biol Chem. 1999 Oct 22;274(43):30969-78. PMID: 10521493


    相關文章

    “3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段

    萬物蓬勃的7月里迎來了2022年ANTOP獎的申報和評審工作。由島津企業管理(中國)有限公司申報的“3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段。獎項名稱:3CoinONE全新體驗......

    青源峰達太赫茲在國際頂級期刊《TrendsinBiotechnology》發文

    青島青源峰達太赫茲科技有限公司研發團隊在國際頂級期刊《TrendsinBiotechnology》(譯名:《生物技術趨勢》)在線發表題為“THzmedicalimaging:frominvitroto......

    科學家將人工智能技術成功用于蛋白質復合物結構預測

    蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......

    發力癌癥分子病理診斷,無錫臻和全資收購TissueofOrigin?

    2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......

    這3個雜志撤回中國學者249篇文章,包含上交、中山等名校

    2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......

    firstinclass胃癌一線療法獲FDA突破性療法

    安進宣布,美國FDA授予其在研firstinclass單抗bemarituzumab突破性療法認定,與改良FOLFOX6化療方案(亞葉酸鈣、氟尿嘧啶和奧沙利鉑)聯用,一線治療FGFR2b過表達和HER......

    金屬所三維伊辛模型精確解研究取得進展

    2007年,中國科學院金屬研究所研究員張志東在英國《哲學雜志》(PhilosophicalMagazine)上發表論文,提出兩個猜想,并在猜想基礎上推定出三維伊辛模型的精確解。被《哲學雜志》審稿人評價......

    腫瘤治療的強心劑,中國學者開發腫瘤治療新策略

    磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......

    llumina宣布推出新型基因分型芯片|支持AllofUs研究計劃

    2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......

    新一代蛋白結構預測技術

    《NatureChemicalBiology》雜志在線版一篇文章介紹,伊利諾斯州立大學JohnA.Gerlt博士率領的研究小組研制出一種新途徑,能夠確定氨基酸序列已知的蛋白的結構和功能。這是首次利用計......

  • <table id="4yyaw"><kbd id="4yyaw"></kbd></table>
  • <td id="4yyaw"></td>
  • 调性视频